RxDoctor Payments Data

Jai Parekh

Interventional Cardiology · Omaha, NENPI 1578915781

Payments from drug & device makers

What this record shows

This record is dominated by grants: $34,500 of the $44,258 with a category attached, or 78.0%. 21 manufacturers reported payments, led by Medtronic at 51.9% of the total. Reporting peaked in 2023 at $36,182 and has fallen 88.4% since, to $4,199 in 2025.

$44,258in general payments, 2019–2025

Across 137 payments — averaging $323.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$23K
  • Abbott$18K
  • Edwards Lifesciences$2K
  • Boston Scientific$447
  • AbbVie$303
  • Cardiovascular Systems Inc.$120
  • plus $498 from 15 others

What the payments were for

  • Grants$34,50078%
  • Travel & lodging$4,20510%
  • Food & beverage$5,33212%
  • Education$2210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,258 in reported general payments places this provider in the 85th percentile of 50 interventional cardiology providers in Nebraska.

See all interventional cardiology providers in Nebraska

Medicare billing

Part B allowed, 2024
$79,192
Medicare patients
414
Services billed
986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin30$22,571
EliquisApixaban24$17,713
EntrestoSacubitril/Valsartan14$15,137
FarxigaDapagliflozin Propanediol12$11,362
Metoprolol Succinate48$692
Ezetimibe11$450
ClopidogrelClopidogrel Bisulfate49$441
Metoprolol Tartrate47$364
Potassium Chloride12$316
Atorvastatin Calcium19$271
Amlodipine Besylate20$169
Spironolactone25$145
Furosemide28$143
Rosuvastatin Calcium26$121
Warfarin Sodium24$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$15$22,57130 claims
NovartisEntresto$23$15,13714 claims
AstraZenecaFarxiga$16$11,36212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 50 interventional cardiology providers in Nebraska.

Other interventional cardiology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →